Annick Chevalier-Place

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Benoît You, Patrick Robelin, Michel Tod et al. · Clinical Cancer Research · 2020 · 132 citations

Medicine, Oncology, Pharmacology +13

Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer

Pierre‐Etienne Heudel, Jean‐Sébastien Frenel, Cécile Dalban et al. · JAMA Oncology · 2022 · 79 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors

Isabelle Ray‐Coquard, Philipp Harter, Domenica Lorusso et al. · JAMA Oncology · 2020 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

Félix Blanc‐Durand, Elisa Yaniz‐Galende, Alba Llop‐Guevara et al. · Gynecologic Oncology · 2023 · 26 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer

Raphaël Leman, Etienne Müller, Angélina Legros et al. · Clinical Cancer Research · 2023 · 26 citations · Full text

Medicine, Gynecology, Oncology +17